Abstract Search

ea0081rc4.8 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Impaired insulin secretion without changes in insulin sensitivity explains hyperglycemia in patients with acromegaly treated by pasireotide LAR

Wolf Peter , Dormoy Alexandre , Maione Luigi , Salenave Sylvie , Young Jacques , Kamenicky Peter , Chanson Philippe

Background: Pasireotide is a second line treatment for acromegaly. Besides the growth hormone (GH) lowering efficacy, clinical use is limited by side effects on glycemic control. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity induced by pasireotide therapy in patients with acromegaly.Methods: We performed a retrospective study in 33 patients. Efficacy (GH and IGF-I concentrations; tumor size) and ...

0 shares

ea0081p671 | Pituitary and Neuroendocrinology | ECE2022

Targeting invasive pituitary adenomas: in vitro studies and in vivo investigations in a murine model of invasive pituitary tumors obtained by orthotopic pituitary GC cells injection

Chasseloup Fanny , Lefevre Etienne , Dormoy Alexandre , Ladurelle Nataly , Mignot Tiphaine , Janot Clement , Hage Mirella , Viengchareun Say , Zizzari Philippe , Chanson Philippe , Buchfelder Michael , Kamenicky Peter

Context: Surgical removal is the primary treatment option for pituitary adenomas. However, pituitary surgery is frequently incomplete because of invasion of extrasellar cerebral structures, notably, of the cavernous sinus. Our objective was to study the molecular basis of the cavernous sinus invasion by pituitary adenomas.Methods: We analyzed a tissue collection of 19 invasive pituitary adenomas with a sample from the intrasellar portion and a sample fro...

0 shares

ea0081oc7.3 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Clinical practice outcomes from 107 patients with Cushing’s syndrome treated with osilodrostat in France

Dormoy Alexandre , Haissaguerre Magalie , Drui Dephine , Demarquet Lea , Do Cao Christine , Guignat Laurence , Vaillant C , Papegaey Anne-Cecile , Raznik Yves , Bras Maelle Le , Salenave S , Raingeard Isabelle , Tauveron I , Christine Vantyghem Marie , Francois M , Delemer B , Luca Florina , Mayer Anne , Petit Jean-Michel , Baudin Eric , Chanson Philippe , Castinetti Frederic , Raverot Gerald , Chabre Olivier , Tabarin Antoine , Young Jacques

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drugs efficacy and safety in patients with Cushings disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushings syndrome (CS) in adults....

2 shares

Endocrine Abstracts

Impaired insulin secretion without changes in insulin sensitivity explains hyperglycemia in patients with acromegaly treated by pasireotide LAR

Targeting invasive pituitary adenomas: in vitro studies and in vivo investigations in a murine model of invasive pituitary tumors obtained by orthotopic pituitary GC cells injection

Clinical practice outcomes from 107 patients with Cushing’s syndrome treated with osilodrostat in France

BiosciAbstracts